Envista 2026 Q2: Revenue of $730 Million, Spark Orthodontics Maintains Double-Digit Growth

Source: Envista 2026 Q2 Earnings Report

Q2 Revenue $730.5 Million / Spark Orthodontics Business Maintains Double-Digit Growth / Implants, Imaging, and Consumables All Report Positive Growth

DentalGoodNews｜August 5, 2026 - Envista Holdings Corporation reported its second quarter 2026 results (period ended July 3), with Q2 revenue of $730.5 million (approximately RMB 4.931 billion), up 7.1% year-over-year, and core sales growth of 5.0%. Both business segments delivered positive growth. The company simultaneously raised its full-year guidance, increasing the core sales growth target from 2%-4% to 3.5%-4.5%.

On profitability, the company reported revenue of $682.1 million (approximately RMB 4.604 billion) in the same period last year. Gross profit for the quarter was $407.0 million (approximately RMB 2.747 billion), with GAAP gross margin of 55.7%, up 150 basis points year-over-year; adjusted gross margin was 55.1%, up 70 basis points year-over-year. This includes $12.6 million (approximately RMB 85.05 million) in tariff refunds, which the company has excluded from adjusted gross profit, adjusted operating profit, and adjusted EBITDA.

Source: Envista 2026 Q2 Earnings Report

On the profit side, the company reported GAAP operating profit of $80.3 million (approximately RMB 542 million), up 73.4% year-over-year; adjusted operating profit of $94.5 million (approximately RMB 638 million), up 32.9% year-over-year, with adjusted operating margin of 12.9% (versus 10.4% in the prior year period). Net income was $53.7 million (approximately RMB 362 million), up 103.4% year-over-year (versus $26.4 million, approximately RMB 178 million, in the prior year period); adjusted net income was $66.5 million (approximately RMB 449 million), up 52.2% year-over-year.

GAAP diluted EPS was $0.33 (approximately RMB 2.23, versus $0.16, approximately RMB 1.08, in the prior year period), and adjusted diluted EPS was $0.41 (approximately RMB 2.77), up 57.7% year-over-year. Adjusted EBITDA was $107.7 million (approximately RMB 727 million), up 27.8% year-over-year, with adjusted EBITDA margin of 14.7%, up 230 basis points from 12.4% in the prior year period.

Source: Envista 2026 Q2 Earnings Report

By business segment, both of Envista's operating segments delivered growth. Specialty Products & Technologies (SP&T), which encompasses Nobel Biocare dental implants and Ormco/Spark orthodontics, reported Q2 revenue of $471.0 million (approximately RMB 3.179 billion), up 5.8% year-over-year, with core sales growth of 3.1% (FX impact of -1.9%, M&A contribution of -0.8%). GAAP operating margin was 12.8% (versus 10.2% in the prior year period), and adjusted operating margin was 14.7% (versus 13.5% in the prior year period).

Specifically, Spark continued to deliver double-digit growth during the quarter; brackets and archwire business experienced high single-digit decline due to inventory build-up by customers in the prior year period; dental implant business core sales growth was in the low single digits.

The other segment, Equipment & Consumables (E&C), which includes DEXIS oral imaging equipment and Kerr consumables, reported Q2 revenue of $259.5 million (approximately RMB 1.752 billion), up 9.5% year-over-year, with core sales growth of 8.5% (FX impact of -1.0%). GAAP operating margin was 17.7% (versus 15.2% in the prior year period), and adjusted operating margin was 20.0% (versus 17.5% in the prior year period). The company noted that E&C has now delivered high single-digit to low double-digit growth for five consecutive quarters, with both consumables and diagnostics businesses achieving high single-digit growth. CEO Paul Keel stated during the earnings call that the segment's growth was driven by market improvement and share gains.

Source: Envista 2026 Q2 Earnings Report

On cash flow, the company reported Q2 operating cash flow of $119.2 million (approximately RMB 805 million) and free cash flow of $105.1 million (approximately RMB 709 million), up from $88.7 million (approximately RMB 599 million) and $76.4 million (approximately RMB 516 million), respectively, in the prior year period. Free cash flow conversion to adjusted net income was 158.0%.

During the quarter, the company repurchased approximately 2.4 million shares for approximately $59.0 million (approximately RMB 398 million); as of quarter-end, approximately $283.0 million (approximately RMB 1.910 billion) remained under the repurchase program. For the first half of the year, cumulative revenue was $1.436 billion (approximately RMB 9.693 billion), with adjusted EBITDA of $206.6 million (approximately RMB 1.395 billion) (versus $163.3 million, approximately RMB 1.102 billion, in the prior year period). Q2 R&D spending was $30.4 million (approximately RMB 205 million), up 7.4% year-over-year (versus $28.3 million, approximately RMB 191 million, in the prior year period), representing an R&D expense ratio of 4.2%.

Source: Envista 2026 Q2 Earnings Report

Based on improved business performance, the company further raised its full-year 2026 outlook: core sales growth target increased from 2%-4% to 3.5%-4.5%; adjusted EBITDA growth target increased from 7%-13% to 11%-14%; adjusted diluted EPS increased from $1.35-$1.45 (approximately RMB 9.11-9.79) to $1.50-$1.55 (approximately RMB 10.13-10.46); free cash flow conversion target remains at approximately 100%.